Dr. Reddy's Laboratories Ltd. Announces the Appointment of New CFO

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (NYSE:RDY - News) today announced the appointment of Mr Umang Vohra as the new CFO of the company. Umang was the Deputy CFO and his elevation has been part of the company’s leadership development and transition programme. He joined Dr. Reddy’s in 2002 from PepsiCo and has been part of several of the company’s key initiatives like Acquisitions, R&D de-risking transactions, and operational improvements in Accounting, Governance and Finance processes.

Mr Saumen Chakraborty, who was the CFO of the company for the past 2 ½ years has taken over a newly created role of President – Corporate and Global Generics Operations. He will now lead the product development, manufacturing and supply chain operations of the generics business, along with corporate functions like Quality, Regulatory, Corporate Medical Services and Pharmacovigilance.

Saumen Chakraborty (47) has over 24 years of experience in strategic and operational aspects of management. Saumen joined Dr. Reddy’s in 2001 as the Global Head of HR and took over as the CFO of Dr. Reddy’s in 2006. He brought in significant robustness to the financial processes, including the transition to IFRS accounting norms and played a key role in raising funds in the second round of ADR. In 2007 he was recognized as the ‘CFO of the Year’ by CNBC in the pharmaceutical and healthcare sector. Saumen is a University topper from Visva Bharati University (Shantiniketan) in Physics, and is an alumnus of IIM, Ahmedabad.

Umang Vohra (37) has over 13 years of experience across various finance & corporate development functions. Prior to joining Dr. Reddy’s Umang has worked with Eicher and PepsiCo. Umang joined Dr. Reddy’s in 2002 in Corporate Finance and has been fast tracked across various challenging roles. With a base degree in computer engineering, Umang has an MBA with a specialization in Finance from TA Pai Institute of Management (TAPMI).

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Established in 1984, Dr. Reddy's Laboratories (NYSE:RDY - News) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection. For further information please see: www.drreddys.com

Contact:

Dr. Reddy’s Laboratories Ltd. Investors and Financial Analysts: Nikhil Shah, +91-40-66511532 nikhilshah@drreddys.com Media: M Mythili, +91-40-66511620 mythilim@drreddys.com

Source: Dr. Reddys Laboratories Ltd.

Back to news